‘Here to Make Miracles’ – San Diego Research Teams Awarded $8.25M in Fight Against Cancer

Curebound ended 2024 by awarding 17 grants totaling $8.25 million to local teams working on cancer research, officials announced Tuesday.

Jan 14, 2025 - 23:35
 0
‘Here to Make Miracles’ – San Diego Research Teams Awarded $8.25M in Fight Against Cancer
An entrance to the Sanford Burnham Pebys Medical Discovery Institute in La Jolla. (Photo courtesy of the Medical Discovery Institute)

Curebound ended 2024 by awarding 17 grants totaling $8.25 million to local institutions and scientists working on cancer research, officials announced Tuesday.

The San Diego-based philanthropic organization awarded teams working on 15 different types of cancer. They include researchers at UC San Diego, Family Health Centers of San Diego, Rady Children’s Hospital, the Salk Institute, San Diego State University, Scripps Health, Sanford Burnham Prebys and the La Jolla Institute for Immunology.

“These 17 grants provide funding for incredibly diverse, innovative and promising cancer research, and would not be possible without our donors – the driving force behind our accomplishments this year,” Curebound CEO Anne Marbarger said.

Curebound has targeted grants, awarding $500,000 to research projects close to clinical trails, and discovery grants, awarding up to $250,000 for more experimental studies.

Dr. Anna Khachatrian Kulidjian of Scripps Health is part of a team conducting research on metastatic prostate cancer.

“Passionate people working together can make cures possible, and cures are miracles,” she said. “We are here to make miracles.”

Curebound also awarded four Catalyst Grants and four Equity Grants of $250,000 each in 2024.

The organization has directed more than $43 million for cancer research projects since 2013.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

CryptoFortress Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.